Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer

Based upon results of the KEYNOTE-522 trial and following approval by regulatory authorities, the addition of pembrolizumab to chemotherapy is now the standard-of-care for the treatment of early triple-negative breast cancer (eTNBC) (Clinical stage II-III). Pembrolizumab is a programmed cell death p...

Full description

Bibliographic Details
Main Authors: Maximilian Marhold, Simon Udovica, Anna Halstead, Mona Hirdler, Muna Ferner, Kerstin Wimmer, Zsuzsanna Bago-Horvath, Ruth Exner, Florian Fitzal, Kathrin Strasser-Weippl, Tim Robinson, Rupert Bartsch
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Early triple negative breast cancer
checkpoint inhibition
neoadjuvant
pembrolizumab
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2275846

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2023.2275846

Similar Items